JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.920
+0.040 (2.13%)
Mar 6, 2026, 4:08 PM HKT
Market Cap778.83M +19.5%
Revenue (ttm)194.77M +2.8%
Net Income-676.78M
EPS-1.63
Shares Out405.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume959,500
Average Volume953,600
Open1.830
Previous Close1.880
Day's Range1.820 - 1.950
52-Week Range1.260 - 6.440
Beta1.97
RSI31.77
Earnings DateMar 25, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 292
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2126
Full Company Profile

Financial Performance

In 2024, HKG:2126's revenue was 158.22 million, a decrease of -8.99% compared to the previous year's 173.86 million. Losses were -590.62 million, -23.10% less than in 2023.

Financial numbers in CNY Financial Statements